** Shares of Syros Pharmaceuticals decline ~64% to $1.83 premarket
** Late on Monday, SYRS said that an interim analysis of data from a mid-stage study for its blood cancer therapy showed a low probability of success for the trial
** Co said it plans to stop enrolling patients in the study testing its therapy, tamibarotenein, in combination with AbbVie
and partner Roche's Venclexta and azacitidine in newly diagnosed, unfit patients with a type of acute myeloid leukemia $(AML.UK)$
** AML is a rare and aggressive type of blood cancer that starts in the bone marrow and can spread to other types of the body
** SYRS said patients currently enrolled in the study will have the opportunity to remain part of the trial at the discretion of investigators
** SYRS is also testing the therapy in patients with myelodysplastic syndrome, a group of cancers that occur when the blood-forming cells in the bone marrow become abnormal
** As of last close, SYRS down ~36% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Comments